BARBARA ANN KARMANOS CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1995-01-01

Employees: 5K

Market Cap: -

Website: http://www.karmanos.org

Clinical Trials

Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer

Not Applicable

Completed

Conditions: Recurrent Prostate Cancer
Adenocarcinoma of the Prostate
Hormone-resistant Prostate Cancer
Stage IV Prostate Cancer

Interventions: Drug: cabozantinib-s-malate
Radiation: fluorine F 18 d-FMAU
Procedure: positron emission tomography
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2013-03-18

Last Posted Date: 2021-08-05

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 20

Registration Number: NCT01812668

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD

Phase 1

Terminated

Conditions: Light Chain Deposition Disease
Primary Systemic Amyloidosis

Interventions: Drug: pomalidomide
Drug: bortezomib
Drug: dexamethasone
Other: Laboratory Biomarker Analysis

First Posted Date: 2012-11-19

Last Posted Date: 2023-05-09

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 18

Registration Number: NCT01728259

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 2 locations

Ultrasound Tomography Using SoftVue in Diagnosing Women With Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Other: ultrasound tomography
Procedure: magnetic resonance imaging

First Posted Date: 2012-10-03

Last Posted Date: 2022-05-26

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 657

Registration Number: NCT01698658

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy

Phase 2

Completed

Conditions: Adenocarcinoma of the Prostate
Stage I Prostate Cancer
Stage IIA Prostate Cancer
Recurrent Prostate Cancer
Stage IIB Prostate Cancer
Stage III Prostate Cancer

Interventions: Biological: bevacizumab
Other: laboratory biomarker analysis

First Posted Date: 2012-08-02

Last Posted Date: 2018-07-31

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 16

Registration Number: NCT01656304

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States

Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies

Phase 1

Terminated

Conditions: Hodgkin's Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Lymphoid Leukemia
Non-Hodgkin's Lymphoma
Myeloid Leukemia

Interventions: Drug: Dasatinib
Other: laboratory biomarker analysis

First Posted Date: 2012-07-18

Last Posted Date: 2020-12-17

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 5

Registration Number: NCT01643603

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery

Phase 2

Withdrawn

Conditions: Breast Cancer Female

Interventions: Drug: oral microencapsulated diindolylmethane
Other: laboratory biomarker analysis

First Posted Date: 2012-06-06

Last Posted Date: 2014-02-12

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Registration Number: NCT01612910

Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma

Phase 1

Terminated

Conditions: Non-Hodgkin's Lymphoma
Multiple
Hodgkin's Lymphoma
Multiple Myeloma
Mycosis Fungoides

Interventions: Drug: Dasatinib

First Posted Date: 2012-06-01

Last Posted Date: 2020-03-16

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 8

Registration Number: NCT01609816

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant

Phase 2

Terminated

Conditions: Stage I Multiple Myeloma
Stage III Multiple Myeloma
Refractory Multiple Myeloma
Stage II Multiple Myeloma

Interventions: Other: pharmacological study
Drug: tacrolimus
Drug: sirolimus
Biological: anti-thymocyte globulin
Drug: fludarabine phosphate
Drug: busulfan
Drug: bortezomib
Procedure: allogeneic hematopoietic stem cell transplantation
Other: laboratory biomarker analysis

First Posted Date: 2012-02-16

Last Posted Date: 2017-04-05

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 1

Registration Number: NCT01534143

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Phase 1

Completed

Conditions: Stage IV Prostate Cancer
Hormone-resistant Prostate Cancer
Recurrent Prostate Cancer
Adenocarcinoma of the Prostate

Interventions: Drug: docetaxel
Drug: pasireotide
Drug: prednisone

First Posted Date: 2011-11-09

Last Posted Date: 2021-03-25

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 18

Registration Number: NCT01468532

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)

Phase 1

Completed

Conditions: Cancer of Pancreas
Cancer of Colon
Pancreatic Cancer
Malignant Tumor of Colon
Pancreatic Neoplasm
Colorectal Cancer
Malignant Neoplasm of Large Intestine
Colon Carcinoma

Interventions: Drug: FOLFOX6
Biological: EGFRBi armed ATC Infusions

First Posted Date: 2011-08-22

Last Posted Date: 2023-05-06

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 15

Registration Number: NCT01420874

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy